Clinical Research Directory

Inclusion Criteria: * Histological diagnosis of adenocarcinoma of the prostate planned for curative-intent standard-of-care radiotherapy (primary or salvage post prostatectomy) or radical prostatectomy with lymph node dissection. * Age ≥ 18 * High risk of regional or distant metastases as defined by any of: * Newly diagnosed and untreated prostate cancer with CAPRA score 6-10, or stage cN1. * Prior history of radical prostatectomy and biochemical failure (PSA\>0.1ng/mL). * Patients must provide study-specific informed consent prior to study entry. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Exclusion Criteria: * Active or prior androgen deprivation therapy (except 5-alpha reductase inhibitor) terminated \< 12 months prior to enrollment. * Prior or planned PSMA PET/CT scan outside of this clinical trial. * Charlson Comorbidity Index \> 5 (see Appendix 2). * Prior curative intent treatment for prostate cancer with local therapy other than surgery (primary radiotherapy or ablative therapies) * Evidence of extra-pelvic nodal disease (M1a) on conventional imaging (if performed) * Evidence of metastatic disease (M1b bone, M1c viscera/soft tissue) on conventional imaging (if performed)